News | Breast Imaging | April 02, 2018

New design improves sensitivity of optical mammography instruments 1,000-fold

Diagnosing Breast Cancer Using Red Light

Schematic diagram for OM instrument: Seven pulsed lasers sequentially illuminate the compressed breast; transmitted light is detected by the 8-channel SiPM probe and the TDC acquires the signal. Credit: Edoardo Ferocino


April 2, 2018 — Optical mammography (OM), which uses harmless red or infrared light, has been developed for use in conjunction with X-rays for diagnosis or monitoring in cases demanding repeated imaging where high amounts of ionizing radiation should be avoided. At the OSA Biophotonics Congress: Biomedical Optics meeting, held April 3-6 in Hollywood, Fla., researchers from Milan, Italy, will report an advance in instrument development that increases the sensitivity of OM by as much as 1,000-fold.

In 2017, an estimated 252,710 new cases of invasive breast cancer were diagnosed in women and 2,470 cases were diagnosed in men1. Many of these diagnoses are made using X-ray mammography. Although standard and widely used, X-ray imaging for breast cancer suffers from both low sensitivity (50-75 percent) and the use of ionizing radiation that cannot be considered completely safe.

The newly-developed instrument replaces two photomultiplier tubes (PMTs) of existing instruments with an eight-channel probe involving silicon photomultipliers (SiPMs) and a multichannel time-to-digital converter. These changes eliminate a pre-scan step that was required to avoid damage to the PMTs. In addition to increased sensitivity, the new instrument is both more robust and cheaper.

While X-ray mammography is widely used and is still the recommended method for routine screenings, its use is limited by the patient’s age, weight or body mass index, the breast tissue itself, whether or not hormone replacement therapy is being used and other issues. In addition, its accuracy — particularly when used in younger women — has been called into question. Other breast imaging techniques, such as magnetic resonance imaging (MRI) and ultrasound, are sometimes suggested, but neither is an effective replacement for X-ray mammography.

Optical imaging methods, on the other hand, have attracted increasing interest for breast cancer diagnosis since both visible and infrared light are highly sensitive to tissue composition. Tumors are characterized by a high volume of blood due to the increased vascularization that occurs as tumors grow. OM can be used to measure blood volume, oxygenation, lipid, water and collagen content for a suspicious area identified through standard X-ray imaging. Collagen measurements are particularly important since this species is known to be involved in the onset and progression of breast cancer.

One major disadvantage to OM imaging is the poor spatial resolution that has been achieved to date. Breast cancer tumors larger than 1 centimeter are very dangerous and more likely to lead to death, so a successful screening technique must be able to resolve smaller lesions. This remains a problem with OM imaging as a stand-alone technique, but combining OM with other imaging methods shows some promise.

A possible advantage to OM, however, is that only gentle pressure need be applied to the breast tissue, in stark contrast to the standard technique for X-ray imaging. In fact, breast compression tends to reduce blood volume in the tissue, which would interfere with the OM image, so some three-dimensional OM detectors being developed use no compression at all, but rather surround the breast tissue with rings of light sources and detectors.

While poor spatial resolution of OM methods remains a challenge, the method does show promise for use in pre-surgical chemotherapy. As Edoardo Ferocino, Politecnico di Milano, Italy, co-author of the work explained, “This technique is able to provide information on the outcome of chemotherapy just weeks after beginning treatment, or possibly even sooner.” Ferocino’s group is planning clinical studies to explore the use of OM to monitor and predict the outcome of chemotherapy.

The investigators in Milan are working with a larger consortium on a project known as SOLUS, “Smart Optical and Ultrasound Diagnostics of Breast Cancer.” This project is funded by the European Union through the Horizon 2020 Research and Innovation Program and aims to combine optical imaging methods with ultrasound to improve specificity in the diagnosis of breast cancer.

For more information: www.osa.org

[1] American Cancer Society. Breast Cancer Facts & Figures 2017-2018. Retrieved from Cancer.org.


Related Content

News | PET Imaging

May 30, 2025 — GE HealthCare recently announced that the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) ...

Time May 30, 2025
arrow
News | Imaging Software Development

May 27, 2025 — DeepLook Medical, a company advancing medical imaging through visual enhancement technology, recently ...

Time May 28, 2025
arrow
News | Mammography

April 29, 2025 — iCAD, a global provider of clinically proven AI-powered cancer detection solutions, has announced a ...

Time April 29, 2025
arrow
News | Mammography

April 24, 2025 — GE HealthCare will feature its latest advancements in diagnostic accuracy and patient-centered breast ...

Time April 24, 2025
arrow
News | Artificial Intelligence

March 10, 2025 — Lunit, a provider of AI-powered solutions for cancer diagnostics and therapeutics, has published a ...

Time March 10, 2025
arrow
News | Artificial Intelligence

Feb. 19, 2025 — SimonMed Imaging and HeartLung Technologies have signed a strategic partnership to offer HeartLung's AI ...

Time March 04, 2025
arrow
News | Ultrasound Imaging

Jan. 28, 2025 — GE HealthCare recently announced it has received 510(k) clearance from the United States Food and Drug ...

Time January 29, 2025
arrow
News | Breast Imaging

Jan. 8, 2025 — ScreenPoint Medical has acquiredf Biomediq A/S, a research-based company focused on the research ...

Time January 10, 2025
arrow
News | Breast Imaging

Dec.11, 2024 — iCAD, Inc., a provider of clinically proven AI-powered cancer detection solutions, recently announced ...

Time December 18, 2024
arrow
News | Mammography

Dec. 5, 2024 — At RSNA 2024, Lunit and Volpara Health announced their unified vision, focusing on a comprehensive ...

Time December 05, 2024
arrow
Subscribe Now